Expression of WISP3 and RhoC genes at mRNA and protein levels in inflammatory and noninflammatory breast cancer in Tunisian patients.

Previous studies have shown the expression WISP3 and RhoC in cell lines of inflammatory breast cancer (IBC). The aim in the current study was to compare the expression of both genes, in biopsy samples collected from Tunisian patients with localized or metastatic breast cancer and patients with IBC. We investigated 127 patients enrolled in Salah Azaiez Institute in Tunis. Using the RT-PCR, we showed the phenotype (WISP3-, RhoC+) is significantly associated with IBC tumors, while the (WISP3+, RhoC-)phenotype is mostly associated to non-IBC tumors. The frequencies of these tumor phenotypes are significantly different between these tumor groups (p = 10(- 7); relative risk or RR = 3.25; confidential interval or CI 95% = 1.90-5.53). Immunohistochemical test revealing the presence of WISP3 and RhoC proteins correlates with the expression in the biopsy of their encoding genes as detected by RT-PCR. In conclusion, it appears that WISP3 and RhoC genes expression status defines a molecular signature of IBC.

[1]  H. Boussen,et al.  Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. , 2008, Seminars in oncology.

[2]  D. Birnbaum,et al.  Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. , 2007, Breast.

[3]  F. Akiyama,et al.  High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer , 2006, Breast cancer.

[4]  Yi Chen,et al.  WISP-3 functions as a ligand and promotes superoxide dismutase activity. , 2006, Biochemical and biophysical research communications.

[5]  W. Thomson,et al.  Wnt-1-inducible signaling pathway protein 3 and susceptibility to juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.

[6]  Alan Hall,et al.  Rho GTPases: biochemistry and biology. , 2005, Annual review of cell and developmental biology.

[7]  Jun Noritake,et al.  Regulation of microtubules in cell migration. , 2005, Trends in cell biology.

[8]  Luc Y Dirix,et al.  Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification , 2004, Clinical Cancer Research.

[9]  M. Labbozzetta,et al.  Expression of WISPs and of Their Novel Alternative Variants in Human Hepatocellular Carcinoma Cells , 2004, Annals of the New York Academy of Sciences.

[10]  A. Ridley,et al.  Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. , 2004, Experimental cell research.

[11]  P. Levine,et al.  Increasing evidence for a human breast carcinoma virus with geographic differences , 2004, Cancer.

[12]  S. Merajver,et al.  Validation of a Tissue Microarray to Study Differential Protein Expression in Inflammatory and Non-Inflammatory Breast Cancer , 2004, Breast Cancer Research and Treatment.

[13]  A. Ridley.  Rho Proteins and Cancer , 2004, Breast Cancer Research and Treatment.

[14]  F. Bertucci,et al.  Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’ , 2004, The Journal of pathology.

[15]  S. Merajver,et al.  RhoC Induces Differential Expression of Genes Involved in Invasion and Metastasis in MCF10A Breast Cells , 2004, Breast Cancer Research and Treatment.

[16]  M. Lotz,et al.  WISP3-dependent regulation of type II collagen and aggrecan production in chondrocytes. , 2004, Arthritis and rheumatism.

[17]  S. Merajver,et al.  WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer , 2003, Breast Cancer Research.

[18]  D. Brigstock.  The CCN family: a new stimulus package. , 2003, The Journal of endocrinology.

[19]  Kyoko Arai,et al.  Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  G. Hortobagyi,et al.  Update on the management of inflammatory breast cancer. , 2003, The oncologist.

[21]  I. Konishi,et al.  Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. , 2003, Gynecologic oncology.

[22]  M. Espié,et al.  Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy , 2002, The Lancet.

[23]  E. Sahai,et al.  ROCK and Dia have opposing effects on adherens junctions downstream of Rho , 2002, Nature Cell Biology.

[24]  S. Merajver,et al.  WISP3 is a novel tumor suppressor gene of inflammatory breast cancer , 2002, Oncogene.

[25]  S. Merajver,et al.  Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. , 2002, The American journal of pathology.

[26]  B. Perbal.  NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues , 2001, Molecular pathology : MP.

[27]  S. Merajver,et al.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. , 2000, Cancer research.

[28]  D. Brigstock,et al.  Connective tissue growth factor: what's in a name? , 2000, Molecular genetics and metabolism.

[29]  Eric S. Lander,et al.  Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.

[30]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  R. Pauli,et al.  Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia , 1999, Nature Genetics.

[32]  D. Botstein,et al.  WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Buzdar,et al.  Inflammatory breast carcinoma incidence and survival , 1998, Cancer.

[34]  Kozo Kaibuchi,et al.  Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase) , 1996, Science.

[35]  C. Nobes,et al.  Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia , 1995, Cell.

[36]  G. Hortobagyi,et al.  Inflammatory breast cancer: a review. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  B. Asselain,et al.  Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis , 1987, Cancer.

[38]  S. Steinberg,et al.  Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. , 1987, Cancer research.

[39]  P. Levine,et al.  Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. , 1985, Journal of the National Cancer Institute.

[40]  P. Levine,et al.  Rapidly progressing breast cancer (poussée Évolutive) in Tunisia: Studies on delayed hypersensitivity , 1978, International journal of cancer.

[41]  S. Narumiya,et al.  Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. , 1998, British Journal of Cancer.